➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Baxter
Express Scripts
Medtronic
Mallinckrodt

Last Updated: July 3, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,649,364


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,649,364
Title:Methods for producing stable therapeutic formulations in aprotic polar solvents
Abstract: Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
Inventor(s): Prestrelski; Steven (San Diego, CA), Sandoval; Michael (Austin, TX), Donovan; Martin (Austin, TX)
Assignee: XERIS PHARMACEUTICALS, INC. (Austin, TX)
Application Number:15/136,650
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound;

Recent additions to Drugs Protected by US Patent 9,649,364

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Xeris GVOKE HYPOPEN glucagon SOLUTION 212097 Sep 10, 2019 RX Yes   Start Trial Y   Start Trial U-2742 TREATMENT OF SEVERE HYPOGLYCEMIA
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 9,649,364

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Xeris GVOKE HYPOPEN glucagon SOLUTION;SUBCUTANEOUS 212097-003 Sep 10, 2019 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF SEVERE HYPOGLYCEMIA   Start Trial
Xeris GVOKE HYPOPEN glucagon SOLUTION;SUBCUTANEOUS 212097-004 Sep 10, 2019 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF SEVERE HYPOGLYCEMIA   Start Trial
Xeris GVOKE PFS glucagon SOLUTION;SUBCUTANEOUS 212097-001 Sep 10, 2019 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF SEVERE HYPOGLYCEMIA   Start Trial
Xeris GVOKE PFS glucagon SOLUTION;SUBCUTANEOUS 212097-002 Sep 10, 2019 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF SEVERE HYPOGLYCEMIA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,649,364

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2016326749   Start Trial
Brazil 112018005800   Start Trial
Canada 2999404   Start Trial
China 108135980   Start Trial
Eurasian Patent Organization 201890704   Start Trial
European Patent Office 3307295   Start Trial
European Patent Office 3352780   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Mallinckrodt
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.